New Product Newswire
new products for 2/19/01
NEW PRODUCT NEWSWIRE
Rx
NEW DRUGS
Organon Inc., West Orange, N.J., (800) 241-8812, has received FDA approval for Cyclessa (desogestrel/ethinyl estradiol oral contraceptive), the first low-dose (less than 30 mcg of estrogen) triphasic contraceptive. Cyclessa is a 25-mcg ethinyl estradiol triphasic OC that offers cycle control comparable to that of 35-mcg ethinyl estradiol triphasic pills. The launch is planned for the first half of 2001.
Under a collaborative agreement with Enzon Inc., Piscataway, N.J., Schering-Plough Corp., Kenilworth, N.J., (908) 298-7409, has received FDA approval for PEG-INTRON (peginterferon alfa-2b) Powder for Injection. The once-weekly monotherapy, which employs Enzon's proprietary PEG technology, is indicated for the treatment of chronic hepatitis C in patients at least 18 years old with compensated liver disease and who were not previously treated with interferon. The drug is administered subcutaneously on the same day each week for one year and may be self-administered. It offers an alternative to recognized combination therapy for chronic hepatitis C. PEG-INTRON is a longer-acting form of INTRON A, a product of Schering-Plough.
Salix Pharmaceuticals, Raleigh, N.C., (919) 862-1000, has launched Colazal (balsalazide disodium), a first-line therapy approved in July 2000 for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is the first new chemical entity approved in 10 yearsand the first new therapy approved in seven yearsfor this indication. Colazal is approved for a course of therapy of up to 12 weeks.
Internal server error